Valproate is a chemically unique and broadspectrum antiepileptic drug. Dose-related side effects include tremor, weight gain, transient hair loss, and limb edema. The first detailed report of valproateinduced hepatotoxicity included one patient with symptomatic hepatic dysfunction and three patients with biochemical changes only. Data from clinical trials showed altered enzymes in 11 % of 1197 moni-
tored patients.2 Asymptomatic decreased levels of circulating fibrinogen also have been reported.3 The observation of transient dose-related hepatotoxicity was followed in 1979 by reports of fatalities associated with valproate treatment. 4,5 Since report of these fatal cases, five reviews6-&dquo; and several isolated cases have been published. Dr Coulter's review in this issue of the Journal emphasizes the state of knowledge regarding mitochondrial metabolism, carnitine, and valproate toxicity. °C linical Risk Patterns Initial and subsequent warnings concerning valproate hepatotoxicity suggested that risk was highest in children under the age of 2 years, especially those treated with multiple anticonvulsants.9 Further, those patients with congenital metabolic disorders, or with severe seizure disorders accompanied by mental retardation, and organic brain diseases also were included in the high-risk group. These clinical guidelines are useful, but may be too restric-tive or insufficiently detailed to allow selection of patients at highest risk.
Fulminant and irreversible hepatic failure cannot be anticipated by laboratory monitoring. However, clinical symptoms may aid in anticipation of fatal hepatotoxic reactions. Vomiting was the most frequently reported initial symptom in fatal cases.5,6 Combined symptoms of nausea, vomiting, and anorexia occurred in 82% of patients with valproate-induced hepatotoxicity. Lethargy, drowsiness, and coma were described in 40% of patients.ll,lz Seizure exacerbation, either loss of control of the patient's usual ictal pattern or appearance of convulsive status epilepticus, occurred in 40% of patients reported.',9 Rechallenge after development of symptoms, with a subsequent fatal outcome has been reported. Several patients treated with valproate developed an illness with a pattern of clinical manifestation usually associated with a fatal outcome, but survived. Those who survived were older than 10 years; however, the clinical pattern occasionally could not be differentiated from that in patients with a fatal outcome.&dquo;
Valproate-induced stupor or coma13,14 has an incidence that ranges from 2% to Specific biochemical disorders associated with valproate hepatotoxicity include urea cycle defects, organic acidurias, multiple carboxylase deficiency, and mitochondrial or respiratory-chain dysfunction.
However, several clinical disorders have also been associated with valproate toxicity.9 These include GM2 gangliosidosis, spinocerebellar degeneration, Friedreich's ataxia, Lafora body disease, Alper's disease, and the myoclonic epilepsy and ragged-red fibers syndrome. In the case of Alper's disease, a subtype is described with associated hepatic disease. 26 This infantile diffuse cerebral degeneration with hepatic cirrhosis has a peak clinical onset by 3 years of age, but frequently begins subtly before this and is characterized by dysmnesia, progressive hypertonia and opisthotonos, partial and generalized seizures (hemiclonic, myoclonic, and frequent status epilepticus or epilepsia partialis continua), and death by 5 years of age. Pathologic findings include diffuse neuronal loss, widespread angiosis, and in the hepatic form, both micronodular cirrhosis and pseudoductal proliferation. Cytochrome aa3 deficiency in muscle, pyruvate carboxylase deficiency, and hepatic pyruvate dehydrogenase complex deficiency (brain) have all been identified in this disorder .27-29 Failure to evaluate may have caused attribution of Alper's-associated fatalities to valproate treatment.
Mechanisms
Why would treatment of a patient with a carboxylic acid such as valproate precipitate metabolic decompensation ? Dicarboxylic aciduria occurs in sys-temic carnitine deficiency, 30,31 in inherited disorders of metabolism such as multiple acyl-coenzyme A (CoA) dehydrogenase deficiency,32,33 and in acquired beta-oxidation impairments such as Jamaican vomiting sickness. 34 Ketogenesis is accordingly limited or absent in these conditions. Symptomatic carnitine deficiency30,31 associated with impaired ketogenesis and enhanced omega-oxidation and dicarboxylic aciduria, may occur in conjunction with episodic hepatocerebral dysfunction reminiscent of Reye's syndrome. As reviewed by Dr Since valproate-induced inhibition of in vitro fatty acid oxidation is reversed by addition of CoASH and carnitine to the reactants, it would appear that valproate causes sequestration of CoASH. 21, 45, 46 Sequestration of CoASH and formation of valproyl-CoA could impair or block several steps in fatty acid oxidation (Figure 1 ). Since fatty acid is esterified to acyl-CoA in the cytosol prior to carnitinemediated transport across the mitochondrial membrane, decreased CoASH would impair formation of acyl-CoA, or conversion of acylcarnitine to acyl-CoA, favoring omega-oxidation with resultant dicarboxylic aciduria. Indeed, valproate-induced sequestration of CoASH may have caused decompensation and dicarboxylic aciduria in a patient with multiple acyl-CoA dehydrogenation defect. 47
Recommendations
No exact clinical testing or specific complex of signs and symptoms form indicators of the patient at greatest risk. We suggest that young children within the clinical groups noted above and those in need of polytherapy should undergo further screening. Since routine accumulation of archival laboratory studies of hepatic function fail to provide information to aid anticipation, we suggest an additional strategy. These children should have baseline routine hematology and chemistry screens and hepatic synthetic functions tests (prothrombin time and partial thromboplastin time), along with further metabolic evaluations including determination of arterial blood gases and ammonia, lactate and pyruvate, carnitine, and urinary organic acids. Clinical assessment should supplant the habit of routine laboratory monitoring. Children or adults being treated with valproate who have vomiting, lethargy, increased seizures, or a flulike syndrome, particularly in the first 6 months of therapy, should have careful clinical evaluation and appropriate detailed metabolic assessment. The intent of this evaluation is to attempt identification of any underlying metabolic abnormality that may have rendered the patient susceptible to valproate toxicity. We agree with Dr Coulter's observation that carnitine administration will be helpful in the treatment of patients with biochemical deficien-cies in which carnitine-related pathways are involved. However, refinement of risk factors coupled with selective screening may improve the clinician's ability to identify patients susceptible to development of valproate-induced idiosyncratic side effects.
